Therapeutic targeting of oncogenic transforming growth factor-β1 signaling by antisense oligonucleotides...

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• The transforming growth factor-β1 (TGF-β1) signaling pathway plays a crucial role in the development and progression of human oral squamous cell carcinoma (OSCC).
• Targeting key signaling pathways offers a potential therapeutic strategy for OSCC.
• Understanding the impact of specific molecular interventions on tumor growth and associated biomarkers is essential.

Purpose of the Study:

• To investigate the efficacy of antisense TGF-β1 oligonucleotides (ODNs) in inhibiting OSCC growth.
• To evaluate the effect of antisense TGF-β1 ODNs on proliferating cell nuclear antigen (PCNA) and matrix metalloproteinase-2 (MMP-2) expression in an OSCC xenograft model.
• To assess the impact of this therapy on tumor growth rate, body weight, and survival duration.

Main Methods:

• In vitro assessment of SCC-9 cell growth inhibition using real-time cell electronic sensing (RT-CES) upon treatment with antisense TGF-β1 ODNs.
• In vivo evaluation using an OSCC xenograft model in nude mice, with daily administration of antisense TGF-β1 ODNs.
• Immunohistochemical analysis of PCNA and MMP-2 expression in tumor tissues from both treatment and control groups.

Main Results:

• In vitro studies demonstrated that antisense TGF-β1 ODNs effectively reduced TGF-β1 expression and inhibited SCC-9 cell growth.
• In the xenograft model, antisense TGF-β1 ODN treatment resulted in a significant decrease in tumor growth rate compared to the control group (P=0.022).
• Immunohistochemistry revealed significantly lower expression levels of PCNA and MMP-2 in tumors treated with antisense TGF-β1 ODNs compared to controls (P<0.05).

Conclusions:

• Antisense TGF-β1 ODN therapy demonstrates significant potential in inhibiting oral squamous cell carcinoma tumor growth.
• The observed inhibition of tumor growth is associated with reduced expression of PCNA and MMP-2.
• While effective against tumor growth, antisense TGF-β1 ODN therapy did not show significant impact on body weight or mean survival time in this model.